Related Experiment Video
Updated: Jul 2, 2025
Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation
Published on: May 20, 2020
Extracellular domain mutations of the EGF receptor differentially modulate high-affinity and low-affinity responses
Jennifer L Macdonald-Obermann1, Linda J Pike1
1Department of Biochemistry and Molecular Biophysics, Washington University School of Medicine, St Louis, Missouri.
Abstract:
The EGF receptor is mutated in a number of cancers. In most cases, the mutations occur in the intracellular tyrosine kinase domain. However, in glioblastomas, many of the mutations are in the extracellular ligand binding domain. To determine what changes in receptor function are induced by such extracellular domain mutations, we analyzed the binding and biological response to the seven different EGF receptor ligands in three common glioblastoma mutants-R84K, A265V, and G574V. Our data indicate that all three mutations significantly increase the binding affinity of all seven ligands. In addition, the mutations increase the potency of all ligands for stimulating receptor autophosphorylation, phospholipase Cγ, Akt, and MAP kinase activity. In all mutants, the rank order of ligand potency seen at the wild-type receptor was retained, suggesting that the receptors still discriminate among the different ligands. However, the low-affinity ligands, EPR and EPG, did show larger than average enhancements of potency for stimulating Akt and MAPK but not receptor autophosphorylation and phospholipase Cγ activation. Relative to the wild-type receptor, these changes lead to an increase in the responsiveness of these mutants to physiological concentrations of ligands and an alteration in the ratio of activation of the different pathways. This may contribute to their oncogenic potential. In the context of recent findings, our data also suggest that so-called "high"-affinity biological responses arise from activation by isolated receptor dimers, whereas "low"-affinity biological responses require clustering of receptors which occurs at higher concentrations of ligand.
Insights
Glioblastoma mutations in the EGF receptor extracellular domain enhance ligand binding and signaling potency. These changes increase cancer cell responsiveness to growth factors, potentially contributing to oncogenesis.
Area of Science:
- Molecular Biology
- Cancer Research
- Cell Signaling
Background:
- Epidermal Growth Factor (EGF) receptor mutations are common in cancers, particularly glioblastoma.
- Glioblastoma mutations often affect the EGF receptor's extracellular ligand-binding domain, unlike other cancers.
- Understanding how these extracellular mutations alter receptor function is crucial for glioblastoma treatment.
Purpose of the Study:
- To investigate the functional consequences of specific EGF receptor extracellular domain mutations (R84K, A265V, G574V) found in glioblastomas.
- To analyze changes in ligand binding affinity and biological responses to seven different EGF receptor ligands.
- To determine how these mutations affect downstream signaling pathways and cellular responsiveness.
Main Methods:
- Analysis of EGF receptor ligand binding affinity for wild-type and mutant receptors (R84K, A265V, G574V).
- Assessment of biological responses, including receptor autophosphorylation, phospholipase Cγ, Akt, and MAP kinase activation.
- Comparison of ligand potency and pathway activation ratios between wild-type and mutant receptors.
Main Results:
- All three glioblastoma mutants (R84K, A265V, G574V) showed significantly increased binding affinity for all seven EGF receptor ligands.
- Mutations enhanced ligand potency for activating receptor autophosphorylation and downstream pathways (PLCγ, Akt, MAPK).
- Mutant receptors exhibited increased responsiveness to physiological ligand concentrations and altered pathway activation ratios, suggesting oncogenic potential.
Conclusions:
- Extracellular domain mutations in EGF receptors found in glioblastomas fundamentally alter receptor function by increasing ligand affinity and signaling potency.
- These alterations lead to heightened cellular responsiveness and modified pathway activation, potentially driving tumor growth.
- Findings suggest distinct mechanisms for high- and low-affinity signaling responses, involving receptor dimers and clusters, respectively.
More Related Videos
Related Concept Videos
02:38Mitogens and the Cell Cycle
01:17Intracellular Signaling Affects Focal Adhesions
Some...
01:22Amplifying Signals via Enzymatic Cascade
01:26Receptor Tyrosine Kinases
01:22Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal
01:27Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include: